Peng Zhao

Peng Zhao


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
MTMeng Tang
Meng Tang
BLBingji Liu
Bingji Liu
XBXiaocui Bu
Xiaocui Bu
PZPeng Zhao
Peng Zhao
Tumor‐associated macrophages (TAMs) contribute to tumor progression, but it is not clear how they are recruited to tumor sites. Here we showed that periostin (POSTN) was present at high levels in ovarian cancer ascetic fluids and was correlated with CD163+ TAMs. The high POSTN level and macrophage infiltration were inversely associated with relapse‐free survival for ovarian cancer patients. In vitro studies showed that coculture with macrophages significantly increased POSTN production in ovarian cancer cells. Further investigation found that POSTN production in ovarian cancer cells was promoted by transforming growth factor‐β generated by macrophages. Moreover, siRNA of POSTN and POSTN neutralizing antibody treatment showed that ovarian cancer cell‐derived POSTN promoted the recruitment of macrophages and modulated their cytokine secretion profile. Collectively, these data indicated that POSTN was an important factor for macrophage recruitment in the tumor microenvironment and is involved in the interactions between macrophages and ovarian cancer cells.

1 April 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
PZPeng Zhao
Peng Zhao
XBXiaocui Bu
Xiaocui Bu
XWXiaofang Wei
Xiaofang Wei
WSWeihong Sun
Weihong Sun
XXXihe Xie
Xihe Xie
DGDaiqing Gao
Daiqing Gao

10 October 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
PZPeng Zhao
Peng Zhao
BWBing Wang
Bing Wang
ZZZhen Zhang
Zhen Zhang
WZWei Zhang
Wei Zhang
YLYan Liu
Yan Liu
M2-polarized tumor associated macrophages (TAMs) play an important role in tumor progression. It has been reported that response gene to complement 32 (RGC-32) promotes M2 macrophage polarization. However, whether RGC-32 expression in macrophages could play a potential role in tumor progression remain unclear. Here we identified that increasing RGC-32 expression in colon cancer and tumor associated macrophages was positively correlated with cancer progression. In vitro studies confirmed that colon cancer cells upregulated RGC-32 expression of macrophages via secreting TGF-β1. RGC-32 expression promoted macrophage migration. In addition, stimulation of HCT-116 cells with the condition mediums of RGC-32-silienced or over-expressed macrophages affected tumor cell colony formation and migration via altered COX-2 expression. In an animal model, macrophages with RGC-32 knockdown significantly decreased the expression of COX-2 and Ki67 in the xenografts, and partly inhibited tumor growth. Together, our results provide the evidences for a critical role of TGF-β1/RGC-32 pathway in TAMs and colon cancer cells during tumor progression.

13 March 2023 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
JZJinju Zheng
Jinju Zheng
XBXiaocui Bu
Xiaocui Bu
XWXiaofang Wei
Xiaofang Wei
XMXuezhen Ma
Xuezhen Ma
PZPeng Zhao
Peng Zhao

1 February 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
DPDa Peng
Da Peng
DSDongfeng Shan
Dongfeng Shan
CDChengcheng Dai
Chengcheng Dai
JLJie Li
Jie Li
ZWZifan Wang
Zifan Wang
XMXuezhen Ma
Xuezhen Ma
Purpose: As a third-generation EGFR TKI has been taken orally, Osimertinib effectively inhibits mutant EGFR, including T790M EGFR resistance mutations. Here, we examined real-world efficacy and tolerability of Osimertinib among Chinese patients with advanced EGFR T790M-mutant NSCLC. Patients and Methods: A total of 106 advanced NSCLC patients who were taking Osimertinib following disease progression after EGFR-TKIs or other treatments were retrospectively recruited in this study. The PFS and OS after Osimertinib treatment were analyzed as the primary endpoints. Results: Osimertinib was used as a second line and ≥ 3rd line treatment in 22.6% and 77.4% of the patients, respectively. DCR and ORR were 93.4% and 57.5%, respectively. Median PFS was 12.4 12 (95% CI, 10.5– 13.5) months. The PFS was 11 (8.0, 14.0) and 12 (10.3,13.7) months (p = 0.373), in patients with and without CNS metastasis, respectively. PFS in 2nd and ≥ 3rd line treatment was 11 (9.0, 13.0) and 12.4 12 (8.9, 15.1) months (p = 0.799), respectively. In patients with EGFR exon 19 deletion and exon 21 L858 mutation, the median PFS was 11 (9.2, 12.8) and 12 (9.2, 14.8) months, respectively (p = 0.833). Median PFS in the monotherapy group and combined anti-angiogenesis group was 11 (9.9,12.1) and 14 (11.2,16.8) months, respectively. Median OS after Osimertinib initiation was 27 (19.6, 34.4) months: 15 (6.9, 23.1) and 27 (22, 32) months in patients with and without CNS metastasis (p=0.027), 27 (20.3,33.7) months and (undefined) as second line or ≥ 3rd line of treatment (p = 0.421), respectively. In patients with exon 19 deletion, the median OS was not reached, and in patients with exon 21 L858 mutations, the median OS was 23 (19.1,29.9) months (p=0.027). Median OS in the monotherapy group was 27 (21.7,32.3) months, and in combined anti-angiogenesis group was not reached (p=0.68). Conclusion: Osimertinib can effectively treat advanced NSCLC with T790M mutations independently of previous treatment lines.

3 December 2019 in Immunological Investigations
Verified
Journal Article
Closed access
CLChangyou Li
Changyou Li
DZDanni Zhu
Danni Zhu
YZYonghui Zhao
Yonghui Zhao
QGQingming Guo
Qingming Guo
WSWeihong Sun
Weihong Sun
PZPeng Zhao
Peng Zhao
The aim of this study: The purpose of this study is to investigate whether the DC cells combined with CIK cells (DC/CIK) and DC activated cytotoxic T cells (DC-ACT) treatment can promote antitumor response and change the immune indicators by targeting the heterogeneous tumor cell populations at a system level. Methods: In this study, 112 patients with cancer were assigned to the DC/CIK treatment and 116 patients received the DC-ACT therapy. We detected the lymphocyte subsets and other immune indicators pre- and post-treatment to evaluate the changes of patient’s immunity and compare the differences in immune status between two adoptive cellular immunotherapies. Results: DC/CIK therapy elevated the percentage of CD3+ HLA-DR+ T cells, NK cells and several serological cytokines such as IL-2, IL-6 after cell infusion (p < .05). DC-ACT therapy could increase the total CD3 + T cells, CD8 + T cells, CD3+ HLA-DR+ cells and IL-12 cytokines after cell infusion (p < .05). The levels of IL-4/IFN-γ, IL-4/IL-12 and IL-6/IL-12 were reduced significantly in the DC-ACT group compared with DC/CIK group. These observations suggested that DC-ACT therapy has more dominance to induce Th1 cytokine response instead of skewing toward the Th2 cytokine profile based on the immunomodulatory properties. Conclusions: These results indicated that DC, CIK, and DC-ACT cells exert anti-tumor activity through the different pathways. Thus, this work may provide valuable insights into the clinical curative effect evaluation of immunocyte therapy and the design of combined immunotherapeutic strategies for malignant tumors.